- Home
- TNGX vs LE Comparison
TNGX vs LE Comparison
Compare TNGX & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- LE
- Stock Information
- Founded
- TNGX 2014
- LE 1963
- Country
- TNGX United States
- LE United States
- Employees
- TNGX N/A
- LE N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- LE Clothing/Shoe/Accessory Stores
- Sector
- TNGX Health Care
- LE Consumer Discretionary
- Exchange
- TNGX Nasdaq
- LE Nasdaq
- Market Cap
- TNGX 248.2M
- LE 274.7M
- IPO Year
- TNGX N/A
- LE N/A
- Fundamental
- Price
- TNGX $2.49
- LE $8.34
- Analyst Decision
- TNGX Strong Buy
- LE Strong Buy
- Analyst Count
- TNGX 6
- LE 1
- Target Price
- TNGX $12.20
- LE $20.00
- AVG Volume (30 Days)
- TNGX 3.5M
- LE 216.7K
- Earning Date
- TNGX 05-12-2025
- LE 06-05-2025
- Dividend Yield
- TNGX N/A
- LE N/A
- EPS Growth
- TNGX N/A
- LE N/A
- EPS
- TNGX N/A
- LE 0.20
- Revenue
- TNGX $40,990,000.00
- LE $1,362,935,000.00
- Revenue This Year
- TNGX N/A
- LE $4.26
- Revenue Next Year
- TNGX N/A
- LE $2.67
- P/E Ratio
- TNGX N/A
- LE $42.16
- Revenue Growth
- TNGX 10.09
- LE N/A
- 52 Week Low
- TNGX $1.03
- LE $7.65
- 52 Week High
- TNGX $12.02
- LE $19.88
- Technical
- Relative Strength Index (RSI)
- TNGX 62.72
- LE 43.30
- Support Level
- TNGX $1.93
- LE $8.52
- Resistance Level
- TNGX $2.67
- LE $9.15
- Average True Range (ATR)
- TNGX 0.39
- LE 0.39
- MACD
- TNGX 0.07
- LE -0.01
- Stochastic Oscillator
- TNGX 55.38
- LE 4.77
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.